



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, March 15, 2012
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
 Lisa Hunt, R.Ph.
 Julia Ozbolt, M.D.

Kort DeLost, R.Ph.
 Beth Johnson, R.Ph.
 Roger Martenau, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Bobbi Hansen, CPhT.

Robyn Seely, Pharm.D.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Kim Eggert, Gilead
 Jason Smith, Gilead

Charissa Anne, J&J
 Tracy Meeks, Roche

Meeting conducted by: Lisa Hunt and Ellie Brownstein.

- 1 Review and Approval of Minutes: Kort Delost moved to approve the minutes. Beth Johnson seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt asked that all the board members sign and turn in the Conflict of Interest form included in their meeting packets. She also reported that the bidding for 2013 contracts has begun. Mississippi has joined the Sovereign States Drug Consortium (SSDC). Ophthalmic antibiotics to be added to the PDL. Lisa asked for clarification from the committee, there was a motion to cover at least 4th generation antibiotic, do they want to prefer Gatifloxacin or Moxifloxacin or leave the decision up to the state. Kort DeLost suggested checking utilization and preferring one over the other based off that.
- 3 Drug Utilization Review (DUR) Board update: Robyn Seely addressed the committee. She reported that the DUR board reviewed Onfi, no PA will be required. The DUR board also reviewed Metoclopramide (long term use), providers will be notified after 12 weeks of therapy. Next month the DUR board will be reviewing Actiq and other opioids.
- 4 **H2 Antagonists:** Melissa Archer provided an overview of the H2 Antagonists. University of Utah recommends preferring one oral dosage form or preferring Cimetidine and one other drug from the class.

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Public Comment: none

Ellie Brownstein stated the both Ranitidine and Famotidine are available as injectable medications and are approved for pediatric usage.

Board Actions: Ellie Brownstien moved that all the agents in the class appear equally safe and efficacious. Kort DeLost seconded the motion. The motion was approved unanimously.

Kort DeLost moved to cover at least one of the agents presented and that Ranitidine must be included (due to utilization, lack of interactions and pediatric indication). Ellie Brownstein seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, April 19, 2012 – Open Meetings Act, Prenatal Vitamins
Meeting Adjourned.
Minutes prepared by Bobbi Hansen.